CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ...

Key Takeaways CHMP issued a positive opinion recommending EU approval of Moderna's new COVID-19 vaccine mNexspike.Per phase III data, MRNA's mNexspike was non-inferior to Spikevax, with 9.3% higher rVE overall.mNexspike showed safety comparable to Spikevax, fewer local reactions, and similar systemic adverse events.Moderna (MRNA) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the EU approval of mNexspike ( ...

Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Moderna. ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

华尔街最受热议且对市场影响显著的研报评级观点现已汇总于此。以下是《The Fly》整理的、投资者 需关注的当日研报评级变动。 五大评级上调 五大评级下调 五大首次覆盖评级 1. 杰富瑞将露露乐蒙（LULU）的评级从 "跑输大盘" 上调至 "持有"，目标价从 120 美元上调至 170 美元。该机构在研报中向投资者表示，公司首席执行官即将离任这一事件是 "重大利好"。 2. 瑞银在分析师团队接手研报覆盖后，将美国航空（AAL）的评级从 "中性" 上调至 "买入"，目标 价从 14 美元上调至 20 美元。瑞银在研报中称，市场尚未充分认识到，随着企业客户营收逐步复 苏，美国航空未来几年有望 "大幅提升" 利润。 3. 摩根大通将花旗集团（C）的评级从 "中性" 上调至 "增持"，目标价从 107 美元上调至 124 美元。 该机构认为，2026 年稳健的经济环境以及强劲的市场相关业务活动，将令花旗相较同行获益更 多。 4. 古根海姆将百时美施贵宝（BMY）的评级从 "中性" 上调至 "买入"，并给出 2026 年 62 美元的目 标价。古根海姆认为，这一目标价对应的投资性价比和管线驱动的风险收益比 "颇具吸引力" ...

行业研究是投资的源动力。元禾控股推出"元动力"系列行研分享，编辑部据此推出《元动力》行业研究专栏，旨在交流行业研究成果，分析行业发展趋 势，探讨未来投资方向。 本期《元动力》行业研究专栏聚焦中美生物医药投资，分享者是元禾控股研究中心（博士后科研工作站）分析师陈铭源博士，将从中美生物医药领域投资 概况、中美医疗体系的差异、"募、投、管、退"视角下的对比与思考等维度进行展开。 中美生物医药领域投资概况 美国VC投资成功案例 美国VC投资成功案例——Moderna | 成立时间 | 2010年 | | --- | --- | | 上市时间 | 2018年 | | 市值 | 1995亿美金(2021年) | | 融资信息 | 20.7亿,A轮-F轮融资 | | 核心技术 | mRNA创新药物 | | 核心产品 | mRNA新冠疫苗2022年,184亿 | | | 美元 | | 投资机构 | Flagship Pioneering解化项目 | | VC角色 | Flagship在孵化到融资阶段共投 | | | 31. 资约5000万美金,2021年所持有 | | | 7.8% 股份约有155.6亿美元 | Modern ...

Jefferies sets a modest price target increase for Moderna, Inc. (NASDAQ: MRNA), indicating a potential 1.28% growth.Investment firm Amundi significantly reduces its stake in Moderna, contrasting with other firms like Natixis Advisors LLC and Charles Schwab Investment Management Inc., which increased their holdings.Despite varying investment strategies, Moderna's stock price has experienced a 2.03% increase, with a market capitalization of approximately $11.57 billion.Moderna, Inc. (NASDAQ: MRNA) is a biotec ...

Jefferies initiated coverage of Moderna, Inc. (NASDAQ: MRNA) with a "Hold" rating and a stock price of $29.62.Amundi reduced its stake in Moderna by 31.9%, selling 425,861 shares.Other investment firms, including Natixis Advisors LLC and Charles Schwab Investment Management Inc., have increased their holdings in Moderna.Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company known for its work in developing mRNA-based vaccines and therapeutics. The company gained significant attention during the COVID-19 pa ...

杰富瑞首次覆盖莫德纳，给予"持有"评级，目标价为30美元。 ...

2021年初，Moderna CEO斯泰芬・邦塞尔在JPM健康会议上意气风发，宣称"THIS is just the beginning （这只是开始）" 。 这句话此后被反复引用和转载数十次，精简地总结了Moderna宏大的雄心：将mRNA新冠疫苗带来的利 润和技术投入到新一代mRNA疫苗和疗法中，改变医学，使Moderna成为全球最大的制药商之一。 但事实并非如此。短短4年，现实与愿景形成刺眼对比，市值蒸发90%，政治打击更是雪上加霜。就在 两周前，Moderna股价创了4年来新低，市值不足100亿美元，对比巅峰近2000亿美元的市值，仿佛大梦 一场。 这绝不仅仅外部环境的问题，HHS部长小罗伯特·肯尼迪主导的政策转向，并非Moderna危机的开端，而 是加速危机的"催化剂"。新冠疫苗之后，mRNA至今还在证明自己的路上，流感疫苗效果一般，RSV疫 苗也不够出色，而年初被寄予厚望的CMV疫苗，III期临床也失败了。 2020 年，新冠疫情爆发，mRNA技术凭借快速研发、高有效性的优势脱颖而出。Moderna 的新冠疫苗 Spikevax率先获批紧急使用，不仅为全球抗疫作出重要贡献，也为公司带来了巨额财富。 ...